Andrew Haydon

发表

A tailored approach to horizon scanning for cancer medicines

P. Ascierto, N. Pavlakis, A. Menzies, 2023, Journal of Cancer Policy.

Adjuvant Systemic Therapy in Melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?

Andrew Haydon, Piotr Rutkowski, Michael Postow, 2024, EJC Skin Cancer.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

C. Coens, A. van den Eertwegh, V. Atkinson, 2024, The Lancet. Oncology.